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Background: Estimated glomerular filtration rate (eGFR) based on either cystatin C or 
creatinine perform similarly in estimating measured GFR, but associate differently with 
cardiovascular disease (CVD) and mortality. This could be due to confounding by non-GFR-
related traits associated with cystatin C and creatinine levels. We investigated non-GFR-
related associations between eGFR and two types of non-traditional risk factors for CVD and 
death: L-arginine/dimethylarginine metabolism and insulin resistance. 
Methods: GFR was measured via iohexol clearance in a cross-sectional study of 1,624 
middle-aged persons from the general population without CVD, diabetes or chronic kidney 
disease. The dimethylarginines were measured using liquid chromatography tandem mass 
spectrometry (LC-MSMS).  Insulin resistance was determined by the homeostasis model 
assessment (HOMA-IR).  
Results: Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), the 
L-arginine/ADMA ratio, and insulin resistance were associated with creatinine-based eGFR 
after accounting for measured GFR in multivariable adjusted analyses. The cystatin C-based 
eGFR showed a similar residual association with SDMA; an oppositely directed, borderline 
significant association with ADMA; and a stronger residual association with insulin resistance 
compared with eGFR based on creatinine. 
Conclusion: Both creatinine- and cystatin C-based eGFR are influenced by non-traditional 






An estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m
2
 is an important risk 
factor for end-stage renal disease, cardiovascular disease (CVD), and death. Epidemiological 
studies have found that eGFR measurements based on cystatin C (eGFRcys) show a stronger 
association with renal and CVD outcomes than GFR estimated according to the creatinine 
level (eGFRcre) [1,2]. Because there is little evidence indicating that cystatin C is more 
effective for estimating GFR compared to creatinine, this superior risk prediction by eGFRcys 
may be caused by confounding of non-GFR determinants of cystatin C and creatinine [3,4]. 
Several studies have shown eGFR to be influenced by traditional CVD risk factors 
independently of the measured GFR (mGFR). In particular, cystatin C seems to be associated 
with obesity, smoking, HDL-cholesterol, triglycerides, hypertension, and C-reactive protein 
(CRP) [5-7]. 
These findings indicate that the estimated risk associated with reduced eGFR in longitudinal 
studies may be confounded, particularly when eGFRcys is used. However, because most 
epidemiological studies reduce confounding by adjusting their survival analysis for these 
traditional CVD risk factors, this may not explain the large difference between eGFRcys and 
eGFRcre risk estimates. Novel CVD risk factors are more difficult to measure in population 
studies and therefore not commonly used for adjustment in survival analysis. Accordingly, 
confounding by these risk factors may contribute to different risk predictions generated 
according to creatinine- and cystatin C-based eGFR. 
In this study, we investigated the association between eGFR based on the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equations [4] and two types of variables 
representing non-traditional CVD risk factors: arginine/dimethylarginine metabolism and 
insulin resistance. Asymmetric dimethylarginine (ADMA), its isomer symmetric 
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dimethylarginine (SDMA), and the L-arginine/ADMA ratio have recently emerged as strong 
and independent risk factors for CVD and death, both in the general population and in high-
risk patients [8-13]. Insulin resistance (IR) also predicts CVD and death in community cohorts 
[14-18], and IR and dimethylarginines are hypothesized to interact in a vicious cycle leading 
to endothelial dysfunction and vascular disease [19-22]. 
In the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6), we measured GFR by 
iohexol clearance as well as the levels of L-arginine, ADMA, SDMA, and IR in a middle-
aged cohort from the general population. Using a cross-sectional design, we aimed to explore 
whether these novel risk factors are determinants of eGFR, after accounting for mGFR. In 
addition, we sought to study the relationship between mGFR and dimethylarginines. The 
relationship between mGFR and IR has been reported previously [23]. 
Subjects and Methods 
Participants   
The RENIS-T6 is a substudy of the sixth population-based Tromsø study (Tromsø 6). Tromsø 
6 included an age-stratified representative sample of 12,984 inhabitants of the municipality of 
Tromsø in Northern Norway [24]. Forty percent of all inhabitants between 50–59 years of age 
and all inhabitants between 60–62 years of age were invited to participate in Tromsø 6. In 
these age groups, 3,564 subjects (65%) completed the main part of the Tromsø 6 survey; of 
these, we excluded 739 who reported previous myocardial infarction, angina pectoris, stroke, 
diabetes mellitus, or renal disease (Figure 1). The remaining 2,825 individuals were invited to 
participate in RENIS-T6, and 2,107 (75%) responded positively. A detailed description of the 
study participants and methods of the RENIS-T6 has been published elsewhere [25]. Briefly, 
77 individuals were excluded because of e.g. allergies to contrast media and 48 individuals 
did not appear at their appointments. Among the remaining 1,982 individuals, we included 
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1,632 individuals according to a predetermined target. Five participants were excluded 
because of technical failure in the GFR measurements, leaving 1,627 persons in the RENIS-
T6 cohort (Figure 1). The characteristics of the RENIS-T6 cohort were comparable to the total 
group of eligible subjects (n=2,825) [26]. In the present investigation, we excluded 3 
individuals because of methylarginine measurement failure.  
The study adhered to the Declaration of Helsinki and was approved by the Regional Ethics 
Committee of Northern Norway. All participants provided informed written consent.  
Measurements 
All study participants met between 8:00–10:00 a.m. in the Clinical Research Unit at the 
University Hospital of Northern Norway after an overnight fast. Blood pressure and blood 
samples were obtained after the participants had been resting for at least at least 5 minutes. 
Serum samples for glucose, creatinine, triglycerides, and cholesterol were measured the same 
day. Serum samples used for measuring the levels of ADMA, SDMA, L-arginine, and insulin 
were stored at -80°C and thawed at the time of analysis. 
Additional information about CVD risk factors was obtained using a questionnaire. Smoking 
status was divided into current smokers and non-smokers. A family history of early 
myocardial infarction was defined as a first-degree relative with myocardial infarction before 
the age of 60 years.  
Iohexol clearance 
GFR was measured as the single-sample plasma clearance of iohexol, as previously described 
in detail [25]. This method has been validated against gold standard methods [27,28]. Briefly, 
5 ml of iohexol (Omnipaque, 300 mg I/ml, Amersham Health, London, U.K.) was injected 
intravenously. The exact time for measuring the iohexol concentration was calculated with 
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Jacobsson’s method based on the eGFRcre [29]. The iohexol concentration was measured 
using high-performance liquid chromatography. The between-run coefficient of variation 
(CV) during the study period was 3.0%. GFR was calculated using the formulas described by 
Jacobsson [29].  
L-Arginine, ADMA, and SDMA measurement 
ADMA, SDMA, and L-arginine were analyzed by LC-MSMS using the Waters Acquity
TM
 
UPLC system with an auto sampler and a binary solvent delivery system (Waters, Milford, 
MA) interfaced to the Waters Xevo TQ-S benchtop tandem quadrupole mass spectrometer 
(Waters, Manchester, UK). Chromatography was performed on a 1.7 µm, 2.1 x 100 mm 
Waters Acquity UPLC BEH Amide column maintained at 50°C. The column was eluted 
isocratically using 10 mM ammonium formate with 0.1 % formic acid in water-acetonitrile at 
0.5 ml/min. Reference standards for ADMA, SDMA and L-arginine were purchased from 
Sigma–Aldrich (St. Louis, MO, USA). The stable isotope-labeled internal standards D7-
ADMA hydrochloride and L-arginine-d7 hydrochloride were obtained from Cambridge 
Isotope Laboratories (Andover, MA, USA). All other chemicals were of analytical grade or 
better. 
Standard samples, quality control samples, and 50 μl of unknown serum samples were mixed 
with 450 μl of the internal standard/precipitation solution in a Waters 96-well PP sample 
collection plate (Waters, Milford, MA). The plate was sealed and placed at 4°C for 30 min 
before centrifugation at 300 × g for 10 min. The plate was then put back on the liquid handler, 
and 50 µL of the clear supernatant was transferred to a second Waters 96-well collection plate 
and diluted with 200 µl water, sealed, and placed in the UPLC autosampler for analysis. 
The between-day CV was <8% for ADMA, SDMA, and L-arginine at three different days. 
Intraday CV were all <5%. The limit of quantification for ADMA and SDMA was 0.01 μM, 
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and that for L-arginine was 0.1 µM. The linear dynamic range (r
2
 > 0.99) for ADMA and 
SDMA was 0.01–10 µM, and that for L-arginine was 0.2-320 µM.  
Other measurements 
We analyzed plasma creatinine using a standardized enzymatic assay (CREA Plus, Roche 
Diagnostics, GmbH, Mannheim, Germany). External quality assessment was provided by 
Labquality, Helsinki, Finland. The inter-assay CV in the study period was 2.3%. Cystatin C 
was measured with a particle-enhanced turbidimetric immunoassay using reagents from 
Gentian (Gentian, Moss, Norway) and a Modular E analyzer (Roche Diagnostics). The inter-
assay CV during the study was 3.1%. External quality control was provided by Equalis 
(www.equalis.se). In 2013, we reanalyzed 300 randomly selected samples with the same 
assay using a Cobas 8000 (Roche Diagnostics) and calibrated the cystatin C measurements to 
the international reference standard [30] (Supplementary Appendix 1). 
The insulin serum samples were thawed and measured with an ELISA kit (DRG instruments, 
Marburg, Germany). The intra- and inter-assay CVs were 4.7% and 6.3%, respectively. 
Insulin resistance was expressed using the HOMA-IR, which was calculated by multiplying 
the fasting glucose (mmol/L) by the fasting insulin (mU/L) divided by 22.5 [31]. 
Three samples of first-void morning spot urine were collected on separate days. Urinary 
albumin and creatinine were measured with commercial kits as previously described [32]. 
ACR was calculated for each urine specimen, and the mean ACR value was used in the 
analyses. 
Ambulatory blood pressure (ABP) was measured with a Spacelab 90207 device (Redmond, 
WA, USA) at 20-min intervals from 08:00 to 22:00. The daytime mean systolic and diastolic 
ABPs were calculated as the weighted mean of the measurements from 10.00 to 20.00. Details 




Means (SD), or median (IQR) values in cases of skewed data, were calculated for baseline 
characteristics and presented for men and women separately. For 19 individuals with missing 
data on ambulatory diastolic blood pressure (DBP), we used values obtained from in-office 
DBP measurements.  
Bias and precision of the estimating equations were calculated as the median and interquartile 
range of eGFR–mGFR, respectively. Accuracy was calculated as the percentage of eGFR 
values within 30% of the mGFR. 
Multiple linear regression analyses were used to explore the association between mGFR and 
eGFR as dependent variables and L-arginine, the dimethylarginines, L-arginine/ADMA ratio, 
insulin, and HOMA-IR as independent variables. We adjusted for the following known 
determinants of GFR or factors that influence GFR estimation: age, gender, use of angiotensin 
converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), BMI, DBP, 
HDL- and LDL- cholesterol, triglycerides, fasting glucose, daily smoking (Y/N), ACR, and 
having a first degree relative with myocardial infarction at <60 years of age. 
Because the statistical method for analyzing non-GFR-related determinants used in previous 
studies has been questioned [7], we used a multivariable approach with general estimating 
equations (GEE) to assess the residual associations between L-arginine, dimethylarginines, 
insulin, the HOMA-IR, and eGFR after accounting for mGFR. This statistical method has 
been described by Rule et al. [7]. In these analyses, mGFR, eGFRcre, eGFRcys, and 
eGFRcrecys were regressed simultaneously on each independent variable after adjustment for 
the same variables as described above. To detect a significant deviation of the risk factor’s 
association with eGFR compared to mGFR, we analyzed the interaction between each 
independent variable and the eGFR method relative to mGFR. In these analyses, we also 
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adjusted for the interaction between eGFR method and all other independent variables. A 
statistically significant interaction was regarded as a non-GFR-related association with eGFR. 
Finally, we used the same method as described above to reanalyze the non-GFR related 
associations between traditional CVD factors and eGFR previously reported from the RENIS-
cohort [6]. 
The statistical analyses were run using STATA 12 (StataCorp, College Station, TX), and 
statistical significance was defined as p<0.05. 
Results 
The RENIS-T6 cohort included 1627 persons, aged 50-62 years, without self-reported 
diabetes, CVD, or kidney disease (Figure 1). Study population characteristics are shown in 
Table 1. 
The bias (precision), calculated as the median and interquartile range of eGFR–mGFR, was 
14.0 (16.1) ml/min/1.73 m
2 
for eGFRcys and 11.4 (13.7) ml/min/1.73 m
2
 for eGFRcrecys. 
The percentage of eGFR values within 30% of the mGFR (accuracy) was 84% for eGFRcys 
and 91% for eGFRcrecys. Bias (precision) and accuracy for eGFRcre in the RENIS-T6 cohort 
were 2.9 (15.4) and 95%, as previously published [25]. 
 Multiple linear regression analyses with mGFR or eGFR as the dependent variable and L-
arginine, ADMA, SDMA, fasting insulin, and the homeostasis model assessment of IR 
(HOMA-IR) as the independent variables are shown in Table 2. In analyses with 
multivariable adjustment, increasing ADMA levels were associated with lower mGFR, 
eGFRcys, GFRcre, and eGFRcrecys, but the association with eGFRcre was small. A higher L-
arginine/ADMA ratio was associated with higher mGFR, eGFRcys, and eGFRcrecys, but not 
eGFRcre (Table 2). SDMA was inversely related to GFR using all methods, with the strongest 
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association identified for mGFR and eGFRcrecys. There were no interactions with gender or 
age, except for a small significant interaction between mGFR and SDMA for age (p=0.02) 
and eGFRcrecys and SDMA for gender (p=0.03) (Table 2). Plots of residuals versus predicted 
values for all regression analysis were inspected and heteroscedasticity was not detected. 
We then assessed the residual associations between the independent variables and eGFR after 
accounting for mGFR using generalized estimating equations (Table 3). Variables 
representing arginine/dimethylarginine metabolism were significantly associated with 
eGFRcre after accounting for mGFR in a model adjusted for age, sex and use of ACEi or 
ARB (Table 2) and in the fully adjusted model (Table 3). There was also a small residual 
association between HOMA-IR and eGFRcre in the fully adjusted model. eGFRcys showed a 
residual association with SDMA, a borderline significant association with ADMA in the 
opposite direction to eGFRcre, and no residual association with the L-arginine/ADMA ratio. 
However, eGFRcys was significantly associated with both insulin and HOMA-IR (Table 3).    
The combined eGFRcrecys estimating equation was residually associated with variables 
representing arginine/dimethylarginine metabolism and HOMA-IR, although the estimates 
were generally small in magnitude (Table 3).  
There were no interactions between age or gender, on the residual association between the 
independent variables and eGFR. Additional adjustment for the use of other antihypertensive 
medications did not influence the regression estimates. 
Among the traditional CVD risk factors; BMI, HDL-cholesterol, triglycerides, fasting 
glucose, ACR and current smoking was residually associated with eGFRcys, whereas only 





We found that dimethylarginines and insulin resistance differed significantly in their 
associations with eGFR compared to mGFR, indicating non-GFR-related associations 
between these novel CVD risk factors and eGFR. eGFRcre was influenced by variables 
representing arginine/dimethylarginine metabolism, while eGFRcys was influenced by 
SDMA and insulin resistance, even after multivariable adjustment for traditional CVD risk 
factors. Both arginine/dimethylarginine metabolism and insulin resistance influenced 
eGFRcrecys, although the associations were weaker. 
 Non-GFR-related determinants of eGFR, and particularly eGFRcys, have been reported in 
previous studies [5-7,34]. In a pooled dataset consisting of patients with CKD, Stevens et al. 
found that several traditional CVD risk factors influenced cystatin C levels after adjusting for 
the mGFR according to Cr-EDTA clearance. In contrast, only small non-GFR related 
associations were found for creatinine [5]. However, these associations were not analyzed in 
multiple regression and were only adjusted for age, sex, and race. In a previous publication 
from the RENIS-cohort, Mathisen et al. found that eGFRcre was influenced by smoking, 
while eGFRcys was influenced by BMI, HDL-cholesterol, triglycerides, and smoking after 
multivariable adjustment [6]. In addition, the residual association between smoking and 
eGFRcys was large and in the opposite direction compared to the association with eGFRcre.  
The statistical method used by Mathisen et al, and other previous studies of non-GFR related 
effects, have been questioned [7]. We therefore reanalyzed the non-GFR related associations 
between eGFR and traditional CVD factors in the RENIS-cohort, and found approximately 
similar non-GFR related associations as reported by Mathisen et al. The magnitudes of these 
estimates were comparable to those with IR and dimethylarginines in the current study 
(Supplemental table 1). 
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In line with the study of Mathisen, Rule et al. found that eGFRcys was more influenced by 
traditional CVD risk factors compared to eGFRcre. In the multivariable adjusted model using 
GEE Rule et al. found BMI, hypertension, and CRP to be determinants of eGFRcys, while 
only urinary creatinine excretion influenced eGFRcre along the non-GFR-related pathway [7].  
In accordance with these data, the authors have argued that eGFRcre is a better proxy for 
mGFR and provides less biased outcomes compared to eGFRcys or eGFRcrecys [5-7]. 
However, our findings challenge the general validity of this conclusion. In particular, the 
dependency of eGFRcre on arginine/dimethylarginine metabolism indicates that a 
confounding relationship exists also between eGFRcre and the risk of CVD and death. 
Neither these metabolites nor insulin resistance is usually measured in longitudinal studies of 
eGFR; accordingly, they cannot be adjusted for to reduce bias in studies of eGFR, CVD, and 
death.  
It is well known that eGFRcre may be falsely high due to reduced muscle mass during chronic 
disease, which may explain the association between high eGFRcre and increased mortality in 
several studies [1,28]. The non-GFR-related effect of ADMA and the L-arginine/ADMA ratio 
found in the current study may bias risk predictions caused by changes in eGFRcre levels in 
the same direction as those observed in reduced muscle mass (increased risk of high eGFR 
and attenuated risk of low eGFR). ADMA inhibits nitric oxide (NO) production from L-
arginine, causes endothelial dysfunction, and has been shown to predict CKD progression as 
well as CVD [35,36]. In the present study, a non-GFR-related effect of 1.5 ml/min/1.73 m
2
 in 
eGFRcre was found per one SD increase in ADMA. This result corresponds to an adjusted 
hazard ratio of 1.3 for mortality in non-diabetic subjects in the Framingham offspring study, 
indicating a considerable increase in risk associated with a small difference in eGFRcre [8]. 
Moreover, the non-GFR related associations of eGFRcre and eGFRcys were opposite for 
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ADMA, which may contribute to the different risk-estimates associated with eGFRcre vs. 
eGFRcys [2].  
We found that eGFRcrecys was less biased by ADMA and SDMA (in the fully adjusted 
model, Table 3) compared to either eGFRcre an eGFRcys, however eGFRcrecys was still 
significantly associated with the L-arginine/ADMA ratio, SDMA, and insulin resistance. Two 
previous studies that evaluated classic CVD risk factors found that eGFRcre was less affected 
than eGFRcys and eGFRcrecys [6,7]. Our results show that eGFRcre may have similar 
problems in relation to non-traditional CVD risk factors and that neither equations are clearly 
superior, despite the fact that eGFRcrecys is more precise for estimating mGFR. 
The non-GFR influence of L-arginine (and the L-arginine/ADMA ratio) on eGFRcre could in 
part be driven by its dependence on homoarginine and/or its involvement in creatinine 
production. Homoarginine, another CVD risk factor, has been associated with both L-arginine 
and eGFRcre [37].  Furthermore, formation of homoargine from L-arginine, via the enzyme 
arginine-glycine amidonotransferase (AGAT), catalyzes synthesis of guaidinioacetate, which 
is subsequently transformed to creatin [38]. 
Similarly, the influence of IR on eGFRcys could relate to metabolic pathways that affect 
cystatin C production, like growth hormone, insulin growth factor 1 and obesity [39], or 
through metabolic parameters such as acylcarnitines which are shown to be associated with 
obesity, IR and decreased eGFR [40]. 
This study had several strengths. First, GFR was measured according to iohexol clearance in a 
large representative sample of the general population. Plasma iohexol clearance has been 
shown to be an accurate method for measuring GFR [27,28]. In addition, the dimethylarginine 
level was determined using LC-MSMS; creatinine and cystatin C assays were both calibrated 
to international standards; and we were able to adjust our analyses for the most important 
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confounders. The cross-sectional design was appropriate to study non-GFR-related 
determinants of eGFR. 
Nonetheless, there were also weaknesses in this study. Only middle-aged Caucasian 
individuals participated, which may have limited the generalizability. In addition, insulin 
resistance was not measured with the gold standard euglycemic clamp method. However, 
HOMA-IR has been shown to correlate well with results obtained using the euglycemic clamp 
technique and remains the preferred method in epidemiological studies [41].   
We conclude that novel CVD risk factors, including ADMA, SDMA, and the L-
arginine/ADMA ratio, represent non-GFR determinants of eGFRcre, while SDMA and IR 
serve as determinants of eGFRcys. Both eGFRcre and eGFRcys may be influenced by non-
GFR-related factors, although not necessarily in the same direction, which may lead to 
different risk prediction in longitudinal studies.  
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Table 1. Study population characteristics
Women Men
(n=823) (n=801)
Age, years 58.1 (3.9) 58.0 (3.8)
Body mass  index, kg/m2 26.8 (4.4) 27.8 (3.5)
Systol ic blood pressure, mmHg 125.4 (17.3) 134.0 (16.8)
Diastol ic blood pressure, mmHg 80.8 (9.3) 86.2 (9.5)
HDL-cholesterol , mmol/l 1.67 (0.41) 1.39 (0.38)
LDL-cholesterol , mmol/l 3.63 (0.87) 3.71 (0.84)
Fasting glucose, mmol/l 5.20 (0.51) 5.51 (0.55)
Dai ly smoking (y/n), % 23 19
Triglycerides , mmol/l 1.0 (0.7-1.3) 1.1 (0.8-1.6)
Albumin/creatinine ratio, mg/mmol 0.37 (0.22-0.65) 0.29 (0.15-0.53)
L-Arginine, µmol/L 92.4 (17.0) 95.1 (16.6)
ADMA, µmol/L 0.43 (0.06) 0.43 (0.06)
SDMA, µmol/L 0.61 (0.10) 0.64 (0.10)
Arginine to ADMA ratio 215.4 (37.9) 225.4 (40.2)
Fasting Insul in, µU/ml 7.8 (5.5-11.1) 9.5 (6.6-13.2)
HOMA-IR, index 1.8 (1.2-2.6) 2.3 (1.6-3-3)
Measured GFR, ml/min/1,73m2 87.8 (14.0) 95.7 (13.7)
GFR estimated by CKD-EPI equations
eGFRcre, ml/min/1,73m2 94.4 (10.0) 95.3 (9.0)
eGFRcys , ml/min/1,73m2 102.2 (12.1) 108.6 (11.7)
eGFRcrecys , ml/min/1,73m
2
101.4 (11.9) 104.6 (10.7)
Numbers  are means  (SD), precentages  or medians  (IQR) 
ADMA; asymmetric dimethylarginine, SDMA; symmetric dimethylarginine, HOMA-IR;







Independent variable Estimate (ml/ (95 % CI) P Estimate (ml/ (95 % CI) P
min/1,73m2) min/1,73m2)
Measured GFR:
L-Arginine per SD increase 0.33 (-0.33 to 0.99) 0.33 0.14 (-0.53 to 0.81) 0.68
ADMA per SD increase -2.24 (-2.91 to -1.58) <0.001 -2.31 (-3.00 to -1.66) <0.001
L-Arginin to ADMA ratio per SD 1.95 (1.28 to 2.61) <0.001 1.86 (1.19 to 2.54) <0.001
SDMA per SD increase -6.72 (-7.31 to -6.13) <0.001 `-6.67
b
(-7.27 to -6.07) <0.001
Insul in per SD increase 0.28 (-0.39 to 0.96) 0.41 0.66 (-0.70 to 0.97) 0.12
HOMA-IR per SD increase 0.58 (-0.10 to 1.26) 0.10 1.05 (0.23 to 1.87) 0.01
eGFRcre:
L-Arginine per SD increase -0.32 (-0.76 to 0.12) 0.16 -0.48 (-0.93 to -0.03) 0.04
ADMA per SD increase -0.67 (-0.79 to -0.55) <0.001 -0.76 (-1.21 to -0.31) 0.001
L-Arginin to ADMA ratio per SD 0.14 (-0.31 to 0.59) 0.53 0.07 (-0.39 to 0.52) 0.77
SDMA per SD increase -4.47 (-4.87 to -4.08) <0.001 -4.57 (-4.96 to -4.17) <0.001
Insul in per SD increase -0.21 (-0.67 to 0.24) 0.36 0.06 (-0.50 to 0.62) 0.85
HOMA-IR per SD increase -0.14 (-0.60 to 0.31) 0.52 0.25 (-0.30 to 0.80) 0.37
eGFRcys:
L-Arginine per SD increase -0.70 (-1.25 to -0.15) 0.01 -0.26 (-0.80 to 0.28) 0.34
ADMA per SD increase -3.00 (-3.54 to -2.46) <0.001 -2.87 (-3.39 to -2.35) <0.001
L-Arginin to ADMA ratio per SD 1.44 (0.89 to 2.00) <0.001 1.86 (1.32 to 2.40) <0.001
SDMA per SD increase -4.77 (-5.28 to -4.26) <0.001 -5.34 (-5.82 to -4.86) <0.001
Insul in per SD increase -1.75 (-2.32 to -1.19) <0.001 -0.86 (-1.53 to -0.19) 0.01
HOMA-IR per SD increase -1.57 (-2.14 to -1.01) <0.001 -0.29 (-0.94 to 0.37) 0.39
eGFRcrecys:
L-Arginine per SD increase -0.64 (-1.17 to -0.11) 0.02 -0.46 (-0.99 to 0.07) 0.09
ADMA per SD increase -2.29 (-2.81 to -1.77) <0.001 -2.26 (-2.77 to -1.74) <0.001
L-Arginin to ADMA ratio per SD 0.98 (0.45 to 1.51) <0.001 1.20 (0.67 to 1.73) <0.001
SDMA per SD increase -5.62 (-6.08 to -5.17) <0.001 -6.04 (-6.48 to -5.59) <0.001
Insul in per SD increase -1.26 (-1.79 to -0.72) <0.001 -0.55 (-1.21 to 0.11) 0.10
HOMA-IR per SD increase -1.10 (-1.64 to -0.57) <0.001 -0.07 (-0.71 to 0.58) 0.84
aAdditional  adjusted for body mass  index, diastol ic blood pressure, HDL-cholesterol , LDL-cholesterol , triglycerides ,
fasting glucose, da i ly smoking (Y/N), a lbumin/creatinine ratio and having a  fi rs t degree relative with myocardia l  
infarction < 60 years  (HOMA-IR not adjusted for fasting glucose). 
bInteraction with age,  p=0.02. Estimates  for the lower, middle and upper age terti les : -7.7 (p<0.001), -6.5 (p<0.001) 
and -6.2 (p<0.001)
Table 2. Multiple linear regression analyses of GFR by different method, and L-arginine, 
methylarginines, insulin and HOMA-IR
Model 1: Adjusted for age, gender and use 
of ACE-i or ARB





















eGFRcre L-arginine per SD increase -0.65 (-1.20 to - 0.09) 0.02 -0.62 (-1.17 to -0.07) 0.03
ADMA per SD increase 1.57 (1.02 to  2.12) <0.001 1.56 (1.00 to 2.11) <0.001
L-arginine to ADMA ratio
per SD increase -1.80 (-2.38 to - 1.23) <0.001 -1.79 (-2.37 to -1.22) <0.001
SDMA per SD increase 2.25 (1.71 to  2.79) <0.001 2.10 (1.55 to 2.66) <0.001
Insul in per SD increase -0.50 (-1.10 to  0.10) 0.10 -0.09 (-0.84 to 0.67) 0.82
HOMA-IR per SD increase -0.73 (-1.34 to - 0.11) 0.02 -0.80 (-1.57 to -0.04) 0.04
eGFRcys L-arginine per SD increase -1.03 (-1.61 to - 0.45) <0.001 -0.40 (-0.94 to 0.13) 0.14
ADMA per SD increase -0.75 (-1.35 to - 0.15) 0.01 -0.55 (-1.12 to 0.01) 0.06
L-arginine to ADMA ratio
per SD increase -0.51 (-1.09 to  0.08) 0.09 0.00 (-0.55 to 0.54) 0.99
SDMA per SD increase 1.95 (1.34 to  2.56) <0.001 1.33 (0.76 to 1.89) <0.001
Insul in per SD increase -2.05 (-2.70 to - 1.41) <0.001 -1.01 (-1.78 to -0.24) 0.01
HOMA-IR per SD increase -2.17 (-2.81 to - 1.52) <0.001 -1.35 (-2.11 to -0.59) <0.001
eGFRcrecys L-arginine per SD increase -0.97 (-1.48 to - 0.46) <0.001 -0.60 (-1.09 to -0.11) 0.02
ADMA per SD increase -0.04 (-0.56 to  0.48) 0.87 0.06 (-0.44 to 0.56) 0.82
L-arginine to ADMA ratio
per SD increase -0.96 (-1.49 to - 0.44) <0.001 -0.67 (-1.17 to -0.16) 0.01
SDMA per SD increase 1.10 (0.59 to  1.61) <0.001 0.63 (0.13 to 1.13) 0.01
Insul in per SD increase -1.55 (-2.12 to - 0.98) <0.001 -0.69 (-1.40 to 0.01) 0.05
HOMA-IR per SD increase -1.69 (-2.27 to - 1.11) <0.001 -1.12 (-1.83 to -0.42) <0.001
bDifference between eGFR and mGFR estimates
cStatis tica l  s igni ficance determined by the s tatis tica l  interaction between each risk factor and eGFR relative to mGFR. 
dAdditional ly adjusted for body mass  index, diastol ic blood pressure, HDL-cholesterol , LDL-cholesterol , triglycerides , 
fasting glucose, da i ly smoking (Y/N), a lbumin/creatinine ratio and having a  fi rs t degree relative with MI < 60 years   
(HOMA-IR not adjusted for fasting glucose).
Table 3. Generalized estimating equations showing residual associations between risk factors and eGFR 
after accounting for mGFRa.
Model 1. Adjusted for age, gender and 
use of ACEi or ARBs
Model 2. As Model 1 and multivariable 
adjustedd
aGeneral ized estimating equations  with eGFR and mGFR as  s tacked dependent variables  regressed on each 
independent variable to compare the di fference in eGFR and mGFR regress ion coefficients .  
Dependent 
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